TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Lymphedema Study for Arm or Leg Lymphedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* a history of lymphedema of one or more limbs (unilateral or bilateral), with a duration of \> 6 months.~Exclusion Criteria:~* Patients with active cancer, infection or bleeding tendency will be excluded.~* We will also exclude patients with medical contraindications to NSAIDs, including history of allergies, know gastrointestinal intolerance, or other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would impair the patients' ability to participate.~* Minors (\<18 years of age) \*\>90 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: Exploratory Group (Type: EXPERIMENTAL): Ketoprofen 225-300 mgs daily, taken orally~Ketoprofen-exploratory group: 225-300 mgs daily for four to six months
- Part 2: Open-label Group (Type: EXPERIMENTAL): Ketoprofen 225 mg daily, taken orally~Open-label group: 75 mgs, three times daily, for four months
- Part 3: Placebo Group (Type: PLACEBO_COMPARATOR): Participants randomized to receive placebo: placebo, three times daily, taken orally~Placebo: 1 capsule, three times daily, for four months
- Part 3: Ketoprofen Group (Type: ACTIVE_COMPARATOR): Participants randomized to receive active medication: ketoprofen 75 mgs., three times daily, taken orally~Ketoprofen: 1 capsule, three times daily, for four months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I or II women~* Aged 20 65 years, and scheduled for gynecologic laparoscopic surgery and IV patient-controlled analgesia (PCA) for postoperative pain control.~Exclusion Criteria:~* Known allergy or intolerance to the study drug~* History of cardiac arrhythmia~* Psychiatric illness~* Chronic treatment with a dopamine antagonist~* Use of opioids or steroids within one week of surgery~* Use of antiemetic within 24 hours before the study~* No ability to use the PCA device~* Gastrointestinal, renal, or hepatic disease~* Insulin-dependent diabetes or obesity with a body mass index \> 35 kg/m2.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- dexamethasone (Type: PLACEBO_COMPARATOR): dexamethasone 5mg iv during anesthesia induction
- dexamethasone, haloperiol 1mg (Type: ACTIVE_COMPARATOR): dexamethasone 5mg iv during anesthesia induction \& haloperidol 1mg iv 30 min before end of anesthesia
- dexamethasone + haloperidol 2mg (Type: ACTIVE_COMPARATOR): dexamethasone 5mg iv during anesthesia induction \& haloperidol 2mg iv 30 min before end of anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. At least one prescription for Tio+Olo combined inhaler or a LABA/ICS combined inhaler between 1 January 2013 and 31 March 2019.~   1. The first dispensing of either Tio+Olo or LABA/ICS combined inhaler will be defined as the index date.~  2. For the main analyses, only fixed dose combination (FDC) inhalers will be included. Sensitivity analyses will also accept free combinations of LABA/ICS.~2. At least one diagnosis of COPD at any time prior to the index date.~3. At least one year of continuous medical and pharmacy health plan eligibility prior to the index date will be required to allow a baseline period for the covariates and identification of new use of the study drugs.~Exclusion Criteria:~1. To increase the likelihood of a true diagnosis of COPD, we will exclude:~   1. All patients less than 40 years of age on the index date, and~  2. All patients with a diagnosis of asthma in the year prior to the index date~2. To limit the population to those without severe lung compromise outside of COPD, we will exclude individuals with lung cancer, interstitial lung disease, or lung transplant identified at any time prior to the index date~3. To restrict the cohort to new users of Tio+Olo or LABA/ICS, we will exclude any individual with use of either Tio+Olo, LABA/ICS, or LABA/LAMA/ICS combination therapy in free or fixed form for at least one year prior to the index date.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients initiating Tiotropium+Olodaterol therapy (Type: None): None
- Patients initiating Long-acting beta agonist/inhaled corticosteroid therapy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with a confirmed clinical diagnosis of a Primary Humoral Immunodeficiency Disease as defined by IUIS (International Union of Immunological Societies) and require treatment with IGIV. Documented agammaglobulinemia or hypogammaglobulinemia~* Male or Female, ages 2 to 70 years~* The subject has received 300-900 mg/kg of a licensed IGIV therapy at 21 or 28 day intervals for at least 3 months prior to this study~* At least 2 documented IgG trough levels of ≥ 500 mg/dL are obtained at two infusion cycles (21 or 28 days) within 12 months prior to study enrollment~Exclusion Criteria:~* Subject has secondary immunodeficiency~* Subject was newly diagnosed with PHID and has not yet been treated with immunoglobulin~* Subject has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency or isolated IgA deficiency with known anti-IgA antibodies~* History of severe reaction or hypersensitivity to IGIV or other injectable form of IgG~* Subject has a lifetime history of at least one thrombotic event including deep vein thrombosis, cerebrovascular accident, pulmonary embolism, transient ischemic attacks, or myocardial infarction~* Subject has received blood products other than human albumin or human immunoglobulin within 12 months prior to enrollment

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- GC5107 (Type: EXPERIMENTAL): GC5107 Immune globulin intravenous (human) solution, 10% liquid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Require lipid-modifying therapy for primary or secondary prevention of cardiovascular disease~* Fasting LDL-C ≥130 mg/dL for primary prevention or LDL-C ≥100 mg/dL for secondary prevention (history of HeFH and/or ASCVD)~* Be statin-intolerant (unable to tolerate 2 or more statins)~Exclusion Criteria:~* Total fasting triglyceride ≥500 mg/dL~* Renal dysfunction or nephrotic syndrome or history of nephritis~* Body Mass Index (BMI) ≥50 kg/m2~* Significant cardiovascular disease or cardiovascular event in the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bempedoic acid (Type: EXPERIMENTAL): bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
- placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Chronic hepatitis C (HCV) genotype 1 infection~2. Chronic Human Immunodeficiency Virus (HIV) -1 infection~3. HCV treatment naive or HCV treatment experienced but only relapsers~4. Age 18 to 70 years~5. Antiretroviral treatment naive or on stable Highly Active Antiretroviral Therapy (HAART)~6. Karnofsky score \>70~7. HCV viral load \>1.000 IU/mL~Exclusion criteria:~1. HCV infection of mixed genotype (1/2, 1/3, 1/4)~2. Evidence of acute or chronic liver due to chronic HCV infection~3. Hepatitis B virus (HBV) infection with presence of HBs-Ag~4. Active malignancy or history or malignancy within the last 5 years~5. Received concomitant systemic antiviral (other than antiretroviral), hematopoietic growth factor or immunomodulatory treatment in 28 days prior enrolment.~6. Decompensated liver disease,as evidenced by ascites, hepatic encephalopathy, esophageal variceal bleeding, and/or laboratory values that add up to \>/= 7 points according tho the Child-Turcotte-Pugh classification~7. Hemoglobin \</=11g/dL for women and \</= 12 g/dL for men~8. Patients with stable cardiac disease and Hemoglobin \<12g/dL~9. Known hypersensitivity to any ingredient of the study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BI201335 12W (Type: EXPERIMENTAL): patient to receive two capsules of BI 201335 once a day for 12 weeks and pegIFN/RBV for 24 or 48 weeks
- BI 201335 24W (Type: EXPERIMENTAL): patient to receive two capsules of BI 201335 once a day for 24 weeks and PegIFN/RBV for 24 or 48 weeks
- BI 201335 24 W (Type: EXPERIMENTAL): patient to receive one capsule of BI 201335 once a day for 24 weeks and pegIFN/RBV for 24 or 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with diagnosis of Type 2 Diabetes Mellitus, treated with diet and exercise or a stable dose of 1 OAD at screening~* Body mass index (BMI) 17 to 40 kg/ m\^2 inclusive~* Subjects who are OAD naïve, HbA1c between 7.0% and 10.0% at Screening and at Visit 2; for subjects who enter the study with 1 OAD, HbA1c between 6.5% and 9.5% at Screening and HbA1c between 7.0% and 10.0% at Visit 2~* Creatinine clearance \>30 mL/min (calculated using the Cockcroft-Gault formula)~Exclusion Criteria:~* History of type 1 diabetes mellitus •Female subject is pregnant, lactating, or \<6 weeks postpartum•~* Clinically significant cardiovascular and/or cerebrovascular disease~* Current ongoing symptomatic biliary disease, clinical signs or symptoms of pancreatitis, or a history of chronic or acute pancreatitis, as determined by the investigator~* Serum amylase \>=3 ×ULN and/or serum lipase \>=2 × ULN and/or subject is experiencing any symptoms possibly related to pancreatitis~* Prior use of a TZD or GLP-1R agonist within 4 months before Screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albiglutide 30 mg weekly (Type: EXPERIMENTAL): Subjects will be randomly assigned to double blind albiglutide 30 mg weekly treatment for 52 weeks
- Albiglutide 50 mg weekly (Type: EXPERIMENTAL): Subjects will be randomly assigned to double blind albiglutide 50 mg weekly until Week 52
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will be randomly assigned to double blind matching albiglutide placebo administered weekly. Subjects will then cross-over to double-blind treatment with albiglutide 30 mg weekly at Week 24 until Week 52
- Liraglutide 0.9 mg daily (Type: ACTIVE_COMPARATOR): Subjects will be randomly assigned to open-label liraglutide for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of AD based on the Japanese Dermatological Association's criteria~* Atopic dermatitis affecting more than or equal to 5%, to less than or equal to 40% of body surface area (BSA, excluding scalp) at the screening and baseline examinations~* IGA score of 2 or 3 at the screening and baseline examinations~Exclusion Criteria:~* Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification of AD, within 28 days prior to the baseline examination

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- 0.3% OPA-15406 (Type: EXPERIMENTAL): Twice daily
- 1% OPA-15406 (Type: EXPERIMENTAL): Twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Systematic Clonidine for Epidural Analgesia in Labour

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parturient is 18 years old~* ASA physical status 1 or 2~* Primiparity~* Singleton~* Gestational age is 36 weeks~* Spontaneous labour with cervical dilatation of 5 cm

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- clonidine (Type: EXPERIMENTAL): None
- no clonidine (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Beat the Blues in Pregnancy Study - Transcranial Magnetic Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects are capable of giving written informed consent and complying with all study procedures;~* Female age 18-39 years old at date of enrollment;~* Pregnant, weeks 14-34;~* Current Depressive Symptoms;~* No change in antidepressant medication at least two weeks prior to study entry if using an antidepressant.~Exclusion Criteria:~* Any alcohol or drug abuse/dependence over the 6 months prior to study entry;~* History of a seizure disorder in subject or first degree relative;~* Anti-psychotic, lithium, or anti-convulsant medications within 2 weeks of study enrollment;~* History of known brain lesions, or severe head trauma;~* Subjects with any metallic object implanted in the skull;~* Subjects with significant cardiac disease;~* Neurological or psychiatric disorders;~* Serious medical illnesses that may compromise patient safety or study conduct;~* Currently taking a drug with known potential for fetal toxicity;~* Previous pregnancy with an adverse fetal outcome;~* Current obstetrical complications~* Actively suicidal;~* History of depression unresponsive to treatment with electroconvulsive therapy (ECT).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Active Transcranial Magnetic Stimulation (Type: ACTIVE_COMPARATOR): 38 pregnant women with MDD will be randomized to receive active 1 Hz right-sided dorsolateral prefrontal cortex (DLPFC) TMS.
- Sham Transcranial Magnetic Stimulation (Type: SHAM_COMPARATOR): 38 pregnant women with MDD will be randomized to receive sham transcranial magnetic stimulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has severe or moderately severe hemophilia A as defined by a baseline factor VIII level \<= 2% of normal, as documented at screening~* The subject is \< 6 years of age~* The subject's legally authorized representative has provided written informed consent~Exclusion Criteria:~* The subject has a history of exposure to factor VIII other than rAHF PFM or more than 3 infusions of commercially available rAHF PFM (i.e., ADVATE) within 28 days prior to screening, as determined by the subject's medical history. Any infusion of factor VIII replacement products prior to the 28-day period excludes the subject from participation~* The subject has received more than 3 infusions of rAHF PFM (commercially available and/or study product) between screening and prior to the initial recovery infusion~* The subject has a detectable inhibitor to factor VIII, as measured in the screening sample by the Nijmegen assay in the central laboratory~* The subject has a history of inhibitor to factor VIII at any time prior to screening~* The subject has a known hypersensitivity to rAHF PFM~* The subject has any 1 of the following laboratory abnormalities at the time of screening:~  1. Platelet count \< 100,000/mm\^3~ 2. Hemoglobin concentration \< 10 g/dL (100 g/L)~ 3. Serum creatinine \> 1.5 times the upper limit of normal (ULN) for age~ 4. Total bilirubin \> 2 times the ULN for age~* The subject has an inherited or acquired hemostatic defect other than hemophilia A (e.g., qualitative platelet defect or von Willebrand's disease)~* The subject is known to be seropositive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV), as determined by the subject's medical history~* At the time of enrollment, the subject has a clinically significant chronic disease other than hemophilia A~* The subject is currently participating in another investigational drug study, or has participated in any clinical study involving an investigational drug within 120 days of the screening visit~* The subject (or the subject's legally authorized representative) is identified by the investigator as being unable or unwilling to cooperate with study procedures~* The subject has received any blood product, including packed red blood cells (RBC), platelets, plasma, or cryoprecipitate

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm - All Participants (Type: EXPERIMENTAL): All subjects enrolled in the study who meet the eligibility criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Project on External Vestibular Prosthesis in Chronic Subjective Dizziness

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Subject population: 20 patients with diagnosis of Chronic Subjective Dizziness (CSD) and 10 normal volunteers.~Inclusion Criteria:~* Subjects will be 25-70 years of age inclusive and pregnant women may participate.~* Patients will have CSD as their primary diagnosis for the cause of their balance and dizziness complaints provided by the Behavioral Medicine Program for Dizziness, a division of the Department of Psychiatry \& Psychology.~* Normal volunteers will have a negative history of otologic \& neurologic disorders and no history of dizziness and balance problems.~* Normal volunteers will have normal findings on a screening office examination for peripheral and central vestibular system involvement (see methods for details of the examination) and screening for normal or symmetrical hearing loss of explainable origin.~Exclusion Criteria:~* Patients with positive indications from testing of peripheral and/or central vestibular system involvement that is felt to be influencing the symptoms reported beyond the CSD alone.~* Patients with mobility restriction that would prevent participating in the tests or the intensive therapy trials.~* Subjects with hearing impairment that interferes with oral communication.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Chronic Subjective Dizziness Syndrome Subjects (Type: EXPERIMENTAL): Subjects diagnosed with Chronic Subjective Dizziness Syndrome (CDS) will wear the BalanceBelt while performing test involving walking and balance.
- Healthy Subjects (Type: ACTIVE_COMPARATOR): Age matched healthy subjects without complaints of balance or dizziness problems will wear the BalanceBelt while performing test involving walking and balance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete